来那度胺联合利妥昔单抗治疗老年弥漫大B细胞淋巴瘤的效果及安全性  

Efficacy and safety of lenalidomide combined with rituximab in the treatment of elderly with diffuse large B-cell lymphoma

作　　者：吴梦婷 钱申贤[2] WU Mengting;QIAN Shenxian(The Fourth School of Clinical Medicine,Zhejiang Chinese Medical University,Hangzhou 310003,China;不详)

机构地区：[1]浙江中医药大学第四临床医学院,杭州市310003 [2]杭州市第一人民医院血液内科,310003

出　　处：《临床合理用药》2025年第7期34-37,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：杭州市医药卫生科技重大项目(Z20210039)。

摘　　要：目的观察来那度胺联合利妥昔单抗治疗老年弥漫大B细胞淋巴瘤(DLBCL)的效果及安全性。方法回顾性分析2021年2月—2024年2月杭州市第一人民医院收治的老年DLBCL患者65例病例资料,按治疗方案不同分为观察组30例和对照组35例,观察组应用来那度胺联合利妥昔单抗治疗,对照组应用R-CHOP方案治疗,2组均以3周为1个周期,治疗6个周期后比较2组近期疗效,治疗前后T细胞亚群、生活质量,不良反应。结果观察组客观缓解率高于对照组(86.67%vs.62.86%,χ^(2)=4.741,P=0.029)。治疗6个周期后,2组CD4^(+)、CD4^(+)/CD8^(+)高于治疗前,CD8^(+)低于治疗前,且观察组变化幅度大于对照组(P<0.01);2组生理健康、社会/家庭生活、情感健康、日常功能、淋巴瘤特定条目评分及总分均高于治疗前,且观察组高于对照组(P<0.05或P<0.01)。观察组不良反应总发生率低于对照组(13.33%vs.37.14%,χ^(2)=4.741,P=0.029)。结论来那度胺联合利妥昔单抗治疗老年DLBCL效果较好,可改善患者免疫功能,提高其生活质量,且不良反应少。Objective To observe the efficacy and safety of lenalidomide combined with rituximab in the treatment of elderly diffuse large B-cell lymphoma(DLBCL).Methods The case data of 65 elderly DLBCL patients admitted to Hangzhou First People′s Hospital from February 2021 to February 2024 were retrospectively analyzed,and were divided into observation group(30 cases)and control group(35 cases)according to different treatment plans.The observation group was treated with lenalidomide combined with rituximab,and the control group was treated with R-CHOP,3 weeks was one cycle in both groups.After 6 cycles of treatment,the short-term efficacy,T cell subsets,quality of life before and after treatment,and adverse reactions were compared between two groups.Results The objective remission rate of observation group was higher than that of control group(86.67%vs.62.86%,χ^(2)=4.741,P=0.029).After 6 cycles of treatment,CD4^(+)and CD4^(+)/CD8^(+)in two groups were higher than before treatment,and CD8^(+)were lower than before treatment,and the change range of observation group were greater than those of control group(P<0.01).Physical health,social/family life,emotional health,daily function,lymphoma-specific scores and total scores in two groups were higher than before treatment,and observation group were higher than control group(P<0.05 or P<0.01).The overall incidence of adverse reactions in observation group was lower than that of control group(13.33%vs.37.14%,χ^(2)=4.741,P=0.029).Conclusion Lenalidomide combined with rituximab is effective in the treatment of elderly DLBCL,which can improve the immune function and the quality of life of patients with less adverse reactions.

关 键 词：弥漫大B细胞淋巴瘤 老年 来那度胺 利妥昔单抗 安全性 

分 类 号：R73[医药卫生—肿瘤]